Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer
Sponsor: Fujian Cancer Hospital
Summary
Clinicopathological data were collected from ovarian cancer patients treated with PARP inhibitors, with follow-up imaging conducted before and after treatment. The efficacy was evaluated according to RECIST criteria, comparing the correlation between different HRD statuses and the efficacy of PARP inhibitors in ovarian cancer.
Official title: The Correlation Between Homologous Recombination Deficiency Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
250
Start Date
2024-01-31
Completion Date
2026-07-01
Last Updated
2024-02-05
Healthy Volunteers
No
Conditions
Interventions
homologous recombination deficiency
Homologous Recombination Deficiency (HRD) refers to a disruption or deficiency in the homologous recombination repair (HRR) pathway, which is a crucial mechanism in cells for repairing DNA double-strand breaks (DSBs). This pathway is particularly important for maintaining genomic stability.